Approval · Notice of Compliance 23158 · 2020
VOSEVI: Notice of Compliance 23158
Issued January 28, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 23158
- Date
- January 28, 2020
- Company
- Gilead Sciences Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To update the vosevi product monograph with respect to hcv-infected adult patients with severe renal impairment and end-stage renal disease (esrd) requiring dialysis
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VOSEVI | Not yet assigned | — |
Medicinal ingredients
- SOFOSBUVIR 400 MG per TAB
- VELPATASVIR 100 MG per TAB
- VOXILAPREVIR 100 MG per TAB